Ra Pharmaceuticals Inc (NASDAQ:RARX) saw a large growth in short interest in the month of December. As of December 29th, there was short interest totalling 1,085,182 shares, a growth of 41.2% from the December 15th total of 768,462 shares. Approximately 11.7% of the shares of the company are sold short. Based on an average trading volume of 175,349 shares, the days-to-cover ratio is presently 6.2 days.

Hedge funds and other institutional investors have recently modified their holdings of the company. Alliancebernstein L.P. bought a new stake in Ra Pharmaceuticals in the 2nd quarter valued at $195,000. The Manufacturers Life Insurance Company boosted its stake in Ra Pharmaceuticals by 30.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,860 shares of the company’s stock valued at $204,000 after purchasing an additional 2,543 shares during the period. Rhumbline Advisers bought a new stake in Ra Pharmaceuticals in the 2nd quarter valued at $241,000. Swiss National Bank bought a new stake in Ra Pharmaceuticals in the 2nd quarter valued at $247,000. Finally, New York State Common Retirement Fund boosted its stake in Ra Pharmaceuticals by 87.8% in the 2nd quarter. New York State Common Retirement Fund now owns 13,900 shares of the company’s stock valued at $260,000 after purchasing an additional 6,499 shares during the period. Institutional investors own 69.64% of the company’s stock.

RARX has been the subject of several research analyst reports. BMO Capital Markets lifted their target price on Ra Pharmaceuticals in a research note on Tuesday, December 5th. Zacks Investment Research upgraded Ra Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.50 target price for the company in a research note on Wednesday, January 10th. Royal Bank of Canada reiterated a “buy” rating and set a $18.00 target price on shares of Ra Pharmaceuticals in a research note on Tuesday, December 5th. Jefferies Group reiterated a “buy” rating and set a $25.00 target price on shares of Ra Pharmaceuticals in a research note on Thursday, September 28th. Finally, Credit Suisse Group lifted their target price on Ra Pharmaceuticals from $19.00 to $23.00 and gave the stock an “outperform” rating in a research note on Friday, November 10th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Ra Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $21.90.

Ra Pharmaceuticals (NASDAQ:RARX) opened at $8.11 on Wednesday. Ra Pharmaceuticals has a one year low of $7.15 and a one year high of $27.84. The company has a market capitalization of $192.10, a P/E ratio of -3.28 and a beta of 6.29.

Ra Pharmaceuticals (NASDAQ:RARX) last issued its earnings results on Thursday, November 9th. The company reported ($0.68) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.06). equities analysts expect that Ra Pharmaceuticals will post -2.46 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Ra Pharmaceuticals Inc (RARX) Short Interest Up 41.2% in December” was first posted by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.watchlistnews.com/ra-pharmaceuticals-inc-rarx-short-interest-up-41-2-in-december/1810096.html.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.